Literature DB >> 8581276

Extrahepatic metabolism of frusemide in anaesthetized rabbits.

J Vergés1, L Héroux, H Maurice, P du Souich.   

Abstract

1. Frusemide is removed from the body by biotransformation and renal secretion, but since frusemide metabolism is not altered in patients with hepatic cirrhosis, the role of the liver may be questioned. The aim of the study was to investigate which organs contribute to the first-pass metabolism and systemic clearance of frusemide. 2. Groups of anaesthetized New Zealand rabbits were administered frusemide proximally (prox) and distally (dist) to different organs, and blood was sampled from the abdominal aorta. The area under frusemide plasma concentrations-time curve (AUC0-infinity) was calculated and frusemide extraction by an organ was estimated from the ratio (AUCdist-AUCprox)/AUCdist. The small intestine extracted 83% of the absorbed dose of frusemide but the first-pass uptake by the liver and lungs was negligible. 3. To assess the contribution of the intestine and the kidneys to the systemic clearance of frusemide, it was injected into the jugular vein and blood was sampled proximal and distal to each organ. The kidneys extracted 24% of frusemide circulating in the renal arteries; on the other hand, the ability of the intestine to extract frusemide from the systemic circulation could not be detected. 4. The lungs did not metabolize frusemide in vitro; the rate of metabolism of frusemide in vitro by kidneys was similar to that estimated in the intestine, and both rates were faster (P < 0.05) than that observed in the liver. 5. It is concluded that in rabbits, presystemic metabolism of frusemide is carried out by the intestine, and that systemic clearance of frusemide is mainly performed by the kidneys, although other organs, such as the intestine and the liver, must contribute to it.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581276      PMCID: PMC1909060          DOI: 10.1111/j.1476-5381.1995.tb15087.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.

Authors:  M Homeida; C Roberts; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

2.  Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.

Authors:  F Andreasen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

3.  Pharmacokinetics of furosemide in advanced renal failure.

Authors:  C M Huang; A J Atkinson; M Levin; N W Levin; A Quintanilla
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

4.  [Aspects of drug metabolism in the lung of the adult rabbit].

Authors:  M De Bernardi; A Ferrara; L Manzo
Journal:  Boll Soc Ital Biol Sper       Date:  1972-03-15

5.  In vivo assessment of extrahepatic conjugative metabolism in first pass effects using the model compound phenol.

Authors:  M K Cassidy; J B Houston
Journal:  J Pharm Pharmacol       Date:  1980-01       Impact factor: 3.765

6.  Enzymatic conjugation of foreign chemical compounds by rabbit lung and liver.

Authors:  T E Gram; C L Litterst; E G Mimnaugh
Journal:  Drug Metab Dispos       Date:  1974 May-Jun       Impact factor: 3.922

Review 7.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

8.  Furosemide kinetics in patients with hepatic cirrhosis with ascites.

Authors:  R Fuller; C Hoppel; S T Ingalls
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

9.  Studies on the persistence of basic amines in the rabbit lung.

Authors:  A G Wilson; R D Pickett; T E Eling; M W Anderson
Journal:  Drug Metab Dispos       Date:  1979 Nov-Dec       Impact factor: 3.922

10.  Disposition of furosemide in functionally hepatectomized dogs.

Authors:  R K Verbeeck; J F Gerkens; G R Wilkinson; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.